P soriatic arthritis (PsA) is a well-known chronic inflammatory arthropathy affecting approximately 40% of patients with psoriasis. [1, 2] Cardiovascular disease (CVD) is prevalent in almost all chronic inflammatory musculoskeletal diseases. [3] It has been well established that rheumatoid arthritis (RA) (relative risk 3.0) and systemic lupus erythematosus (relative risk 6.0) are independent risk factors for coronary heart disease. [1] Recently published data revealed that patients with PsA also had an increased risk for endothelial dysfunction and CVD, although the relative risk of CVD was only 1.6 [2, 4] and CVD accounted for approximately one-third of all deaths among PsA patients. [5] However, it was unclear if such an increased risk for CVD and mortality in PsA was entirely because of traditional atherosclerotic risk factors. [6] Chronic inflammatory status is a well-defined nontraditional risk factor for atherosclerosis. [7] During an inflammatory state, the expression and activation of several proinflammatory cytokines, including interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF) alpha have been documented in the pathogenesis of both atherosclerosis and PsA. [1] As a result of all those common pathways, endothelial function, as a hallmark of atherosclerosis, is impaired. [8, 9] To address this issue in detail, previous studies have investigated the association of PsA with subclinical atherosclerosis, as a well-known indicator of CVD. [10, 11] Subclinical atherosclerosis can be assessed by measuring either flow-mediated dilatation (FMD) [12] and/or carotid intima media thickness (CIMT). [13] However, there have been conflicting results regarding such an association between PsA and markers of subclinical atherosclerosis. This research was designed to assess the presence of subclinical atherosclerosis using FMD and CIMT in patients with PsA in comparison with patients with RA and with healthy control subjects.
METHODS

Study population
In this parallel group observational study, a total of 30 patients with PsA diagnosed according to the classification of psoriatic arthritis criteria, [1] 30 patients with RA diagnosed according to the American College of Rheumatology/European League Against Rheumatism criteria, [14] and 30 healthy control subjects who were admitted to a tertiary center rheumatology outpatient clinic were enrolled. Gender, age, and body mass index (BMI)-matched RA patients and healthy controls were selected as comparison groups for the study. Healthy control subjects were randomly selected from the patients of our check-up unit. Patients with the diagnosis of any CVD (stable coronary artery disease, peripheral artery disease, cerebrovascular disease, acute coronary syndrome); preexisting traditional cardiovascular risk factors, such as arterial hypertension, diabetes mellitus, family history of premature coronary heart disease, or dyslipidemia; chronic infectious or inflammatory disease; or liver or kidney failure were excluded from the study.
Informed consent was obtained from each patient before enrollment. The study was conducted in compliance with the principles outlined in the Declaration of Helsinki and was approved by the Institutional ethics committee.
Demographic data (gender, age), BMI, smoking history, and disease characteristics of the patients were recorded. A tender joint count, swollen joint count, and the Disease Activity Score (DAS)-28 tool were used for joint activity assessment. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) measurements were used for acute phase reactants. The last visit fasting glucose level and lipid profile results (total cholesterol, high-density lipoprotein [HDL], low-density lipoprotein [LDL] , and triglycerides) were also noted.
Assessment of brachial artery flow-mediated dilatation
A blinded cardiologist performed the measurement of brachial artery diameters. Calculation of FMD using brachial artery reactivity was performed using 2-dimensional grayscale and color-flow Doppler as well as vascular imaging using an echocardiography device (Vivid 5; GE Healthcare, Inc. Chicago, IL, USA) with a 10-MHz vascular ultrasound probe as previously described. [15] Participants fasted for 8 to 12 hours and all medications were withheld before the study. Par- After resting in the supine position for 10 minutes in a quiet, air-conditioned room, the brachial artery was prepared for measurements. The brachial artery was scanned longitudinally at 2 to 5 cm above the antecubital crease. This location was marked on the skin and all subsequent measurements were performed at the same location. To calculate the FMD, percent diameter changes were determined as follows: (diameter after reactive hyperemia−baseline diameter)/baseline diameter×100. To avoid confounding effects of arterial compliance and its cyclic changes in dimension, all of the measurements were obtained at the peak of the R-wave of the electrocardiogram. The mean diameter of the brachial artery was determined at baseline and then continuously for up to 5 minutes after reactive hyperemia. [16] Assessment of carotid intima media thickness CIMT was also measured by an experienced cardiologist who was blinded to the clinical data of the participants. CIMT is defined as the distance between the media-adventitia interface and the lumen-intima interface. Measurements were performed using a duplex ultrasound system with a 10-MHz scanning frequency in the B-mode, pulsed Doppler mode, and color mode using the Vivid 5 device. CIMT was measured at the far wall of the right and left common carotid arteries, 10 to 20 mm proximal to the carotid bulb. The mean of 5 measurements of each artery was recorded. The reproducibility of the CIMT measurements was examined by conducting another scan 1 week later on 10 patients. In our laboratory, the intra-observer variability is below 10% for CIMT (4.1±1.2%), demonstrating good reproducibility. A search was made of the common, internal, and external carotid arteries for carotid plaques. The presence of carotid plaque was defined as intima-media thickening >1.0 mm. CIMT measurement was always performed in plaque-free regions.
Statistical analysis
Continuous variables were presented as mean±SD or median (minimum-maximum), whereas categorical variables were presented as percentages. The Kolmogorov-Smirnov criterion was used for the assessment of normality. (Fig. 1) . While both the median right and left CIMT were significantly greater in RA patients compared with the healthy controls (p=0.039 and p=0.002, respectively), there tients compared with the healthy controls (p<0.001).
The demographic, clinical, and laboratory data of the study groups are presented in Table 1 . The FMD percentage was significantly lower in the PsA and RA patients than in the healthy participants was no difference between the PsA patients and the healthy controls in regard to right and left CIMT (Fig.  2) . The mean log10 (CIMT) was also significantly higher in the RA patients than it was in the healthy controls (p=0.006). Carotid plaque was observed in 4 (13.3%) patients with RA, but no carotid plaque was seen in the PsA patients or the healthy controls (Table  2 ). There was no correlation between the DAS-28 results and FMD (r=0.058; p=0.688) or log10 (CIMT) (r=-0.119; p=0.405). However, there was a significant positive correlation between the duration of PsA and log10 (CIMT) (r=0.283; p=0.033) ( Fig. 3 ; Table 2 ). In addition, correlation analysis revealed that there was a significantly positive correlation between CRP level and CIMT (r=0.315; p=0.01) and a trend for a positive correlation between ESR and CIMT (r=0.197; p=0.068). There was no significant correlation between FMD and either ESR or CRP. The FMD and CIMT values were similar between patients with wither an active or remission phase disease diagnosis.
DISCUSSION
Our study results indicated that PsA and RA patients demonstrated significantly lower FMD values compared with healthy controls. However, CIMT was only higher in RA patients compared with healthy controls and was similar between PsA patients and healthy controls. Additionally, there was a positive correlation between the duration of disease and log10 (CIMT) values, but no correlation was found between disease activity and parameters of endothelial dysfunction or subclinical atherosclerosis.
PsA is known as one of the most common chronic immune-mediated inflammatory arthropathies. [1] Previous studies have reported that traditional cardiovascular risk factors were more prevalent in PsA, as in other chronic inflammatory rheumatological diseases, [6, 17, 18] and that CVD and cardiovascular mortality are also significantly increased in these patient groups compared with the general population. [19, 20] RA is the prototype and most common form of inflammatory and immune-associated arthritis, and has the greatest impact on cardiovascular outcomes. Therefore, scientific statements have been developed by rheumatology societies for RA patients to reduce cardiovascular risk. [21] It has also been studied and observed that CVD risk is increased in other forms of inflammatory rheumatic diseases like PsA. [10, [22] [23] [24] [25] [26] However, the increased cardiovascular morbidity and higher in the patients with RA than in the healthy controls, but there was no significant difference in CIMT between the PsA patients and the controls. GonzalezJuanatey et al. [25] reported that the FMD percentage was significantly lower in patients with PsA without CV risk factors or clinically evident CVD compared with healthy controls, indicating endothelial dysfunction in PsA as a potential basis for the association between PsA and atherosclerosis. [34] However, there have been contradictory results regarding the increased risk of subclinical atherosclerosis assessed by CIMT in patients with PsA in case-control studies and metaanalyses. [2, 10, 11, 23, 24, 35, 36] We proposed that the main reason for a non-significant difference in CIMT between PsA and healthy controls was the greater use of anti-TNF-alpha treatment, as a stronger anti-inflammatory agent, compared with the RA patients in our study and other studies. [37, 38] Previous studies have shown that anti-TNF-alpha treatment in psoriatic patients reduced CIMT. [38] Patients with PsA without clinically evident CVD or traditional CV risk factors in our study population demonstrated an impaired endothelial functions as a precursor of atherosclerosis, but no difference in CIMT as a marker of subclinical atherosclerosis when compared with healthy controls. Additionally, HDLcholesterol levels were significantly different between the PsA and RA patients in our study (lower in PsA patients). Although a low level of HDL-cholesterol is significantly linked to atherosclerotic disease and cardiovascular adverse events, the assessment in inflammatory conditions is more complex as a result of a reduction in HDL-cholesterol level as an acute phase reactant and changes in structure. [39] We thought that a pathological inflammatory process, rather than a cholesterol hypothesis (regarding low HDL-cholesterol) may have more importance in the development of atherosclerosis among inflammatory rheumatological diseases.
As a clinical implication of our study results, the CV risk of patients with PsA may be evaluated using indicators of endothelial dysfunction (FMD) and subclinical atherosclerosis (CIMT). As a proposal, such a screening program may help in the early diagnosis of CVD and reducing CV morbidity and mortality.
Our study results should be interpreted with some significant limitations. First, our small, non-randomized parallel group study has no power to show any causality between PsA and subclinical atheroscleromortality in patients with PsA cannot entirely be explained by traditional cardiovascular risk factors, and chronic inflammatory status may act as an independent risk factor for CVD in these patients, like RA. [27, 28] Therefore, the association between PsA and subclinical atherosclerosis and endothelial dysfunction, proven indicators of CVD, is still a matter of research. In our study, we aimed to assess the presence of endothelial dysfunction and subclinical atherosclerosis in patients with PsA as the primary patient group. We also included patients with RA as the prototype and most common form of chronic inflammatory arthritis associated with CVD as a secondary patient group, as well as a healthy group for comparison.
It is apparent from the literature that atherosclerosis is linked to an inflammatory pathological processes and significantly associated with chronic inflammatory and immune-mediated diseases. [7, [29] [30] [31] Therefore, chronic inflammatory status and abnormal immune pathways in inflammatory and immune-mediated rheumatological diseases may be directly associated with subclinical and clinical atherosclerosis and adverse CV outcomes. The impact of inflammation and immunity during the atherosclerotic process may be more prominent in the absence of traditional CV risk factors. Thus, we included patients with PsA and RA without a previous history of CVD or traditional CV risk factors and aimed to assess the impact of the rheumatological disease process on endothelial dysfunction and subclinical atherosclerosis. The positive correlation between CRP level and CIMT in our study group supports the hypothesis that the atherosclerotic pathophysiological process is linked to chronic inflammation. Impaired endothelial dysfunction is a precursor of atherosclerosis and has consistently been associated with increased CV risk. [8] Ultrasonography is used to noninvasively assess endothelial function using the FMD percentage in the brachial artery. [12, 16] CIMT, determined by ultrasonography, is a valuable, non-invasive surrogate indicator of clinical CVD and potential adverse outcomes and provides information about the subclinical stage of the atherosclerotic disease. [32, 33] In our study, we found that FMD was significantly lower in patients with PsA and RA patients compared with healthy controls. These findings showed that endothelial function was significantly impaired in PsA and RA patients. Furthermore, CIMT was also significantly sis, and the study results cannot be generalized to the whole PsA population due to the absence of traditional CV risk factors. Second, most of our PsA patients were using biological agents, which might impact the measurements of endothelial function and subclinical atherosclerosis. Third, we did not assess the level of homocysteine, vitamin B12 or folate, which have been closely associated with endothelial function and shown to be affected in immune mediated disorders. Finally, approximately half of both the PsA and RA groups were in the active form of their disease, which might impact FMD measurement.
In conclusion, there was an increased risk of impaired endothelial function in the PsA patients without clinically evident CVD or traditional CV risk factors that was similar to RA patients as a prototype for high CV risk. Chronic inflammatory status in the PsA disease process may be the most likely risk factor for the occurrence of early atherosclerotic changes in these patients. However, further randomized controlled studies are needed to understand the causal relationship between PsA, inflammation, immunity, and atherosclerosis. Therefore, it is reasonable to assess patients with PsA with regard to CV risk as well as other system findings.
